Immunocellular Therapeutics Stock Total Debt
ImmunoCellular Therapeutics fundamentals help investors to digest information that contributes to ImmunoCellular Therapeutics' financial success or failures. It also enables traders to predict the movement of ImmunoCellular Pink Sheet. The fundamental analysis module provides a way to measure ImmunoCellular Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoCellular Therapeutics pink sheet.
ImmunoCellular |
ImmunoCellular Therapeutics Company Total Debt Analysis
ImmunoCellular Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current ImmunoCellular Therapeutics Total Debt | 2.78 M |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, ImmunoCellular Therapeutics has a Total Debt of 2.78 M. This is 99.9% lower than that of the Biotechnology sector and 99.14% lower than that of the Health Care industry. The total debt for all United States stocks is 99.95% higher than that of the company.
ImmunoCellular Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.ImmunoCellular Therapeutics is currently under evaluation in total debt category among its peers.
ImmunoCellular Fundamentals
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 933.15 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.78 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 1.51 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (2.31 M) | ||||
| Short Ratio | 4.13 X | ||||
| Earnings Per Share | 28.91 X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 2.21 M | ||||
| Total Asset | 30.08 M | ||||
| Retained Earnings | (74.14 M) | ||||
| Working Capital | 22.29 M | ||||
| Current Asset | 24.56 M | ||||
| Current Liabilities | 2.27 M | ||||
| Z Score | -2.8 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |